In the new phase of the collaboration, cohorts of millions of behavioral health patients and related de-identified clinical data from Veradigm will be added to Holmusk’s NeuroBlu Database, a source of real-world data. The data will show how behavioral health care is delivered.
Behavioral health generally refers to mental health and substance use disorders, life stressors and crises, and stress-related physical symptoms. Behavioral health care refers to the prevention, diagnosis and treatment of those conditions.
According to the Substance Abuse and Mental Health Services Administration (SAMHSA) one in five adults in the US have a clinically significant mental health or substance use disorder.
Veradigm says it is also making an additional financial investment in Singapore and New York-based company, Holmusk, building on the collaboration launched earlier this year, when Veradigm became the lead investor in Holmusk’s Series B financing round.
“This strategic investment represents significant growth for our NeuroBlu Database, enabling us to move closer to our vision of creating a single source of truth for behavioral health,” said Nawal Roy, Holmusk’s founder and CEO.
“This is a crucial step as we work to help eliminate the gaps in evidence, information, and learning that have held the behavioral health industry back from moving to an outcome-based reimbursement system and a learning healthcare system.”
The collaboration expands Holmusk’s NeuroBlu Database by millions of patients. The database will now be able to power more research and address challenging behavioral health questions that require the creation of targeted research cohorts.
“We look forward to taking this next step in our collaboration with Holmusk,” said Rick Poulton, Veradigm’s chief executive officer.
“Holmusk’s expertise in preparing clinical real-world data for analysis, including mapping the data to a common data model, will be invaluable in unlocking new insights from our existing resources. We also believe it will enable the creation of much-needed evidence to improve behavioral health outcomes around the world.”
Back in January this year (2023) Veradigm Inc., formerly Allscripts Healthcare Solutions, Inc., announced the investment in Holmusk, as part of Holmusk’s $45 million series B financing round.
The round was led by Veradigm, with participation from current investors including Heritas Capital, Health Catalyst Capital, Novartis (dRx Capital), and Northwell Holdings, the venture investment arm of Northwell Health, as well as other previous investors.
At that time, Poulton said: “Mental and behavioral health is a serious global health problem that has only increased during and post the COVID-19 pandemic.
“Holmusk has proven expertise to create the evidence needed to improve mental health. We are proud to equip the company with the resources needed to advance this important work.”
Since 2021, Holmusk has established multiple partnerships with hospitals and medical research institutes worldwide to help advance behavioural health research while growing its platform.
